

# Validation of the Dutch version of the 22-item Sino-Nasal Outcome Test (SNOT-22)\*

Dirk A.E. Dietz de Loos<sup>1,2</sup>, Marjolein E. Cornet<sup>3</sup>, Wytske J. Fokkens<sup>1</sup>, Sietze Reitsma<sup>1</sup>

Rhinology Online, Vol 5: 128 - 132, 2022

<http://doi.org/10.4193/RHINOL/22.015>

<sup>1</sup> Department of Otorhinolaryngology, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands

**\*Received for publication:**

<sup>2</sup> Department of Otorhinolaryngology, Isala Hospital, Zwolle, The Netherlands

June 11, 2022

<sup>3</sup> Department of Otorhinolaryngology, Alrijne Hospital, Leiden, The Netherlands

**Accepted:** July 5, 2022

**Published:** September 16, 2022

## Abstract

**Background:** The 22-item Sino-Nasal Outcome Test (SNOT-22) is a widely used questionnaire to measure disease-specific health-related quality of life in patients with chronic rhinosinusitis (CRS). The Dutch version has not been validated yet.

**Methods:** The SNOT-22 was translated through a forward-backward translation technique and validated by a test-retest protocol in CRS patients, a responsiveness analysis in CRS patients treated with dupilumab, while using healthy individuals as controls.

**Results:** The Dutch SNOT-22 showed excellent test-retest properties, good responsiveness to treatment with dupilumab, and a clear distinction between outcomes of CRS patients and healthy controls.

**Conclusion:** The Dutch version of the SNOT-22 is a valid outcome measure in CRS patients.

**Key words:** sinonasal outcome test, health-related quality of life, SNOT-22, patient-reported outcome measure, chronic rhinosinusitis

## Introduction

Chronic rhinosinusitis (CRS) is a relatively common chronic disease affecting between 4-11% of Western populations<sup>(1,2)</sup>.

The diagnostic construct is based on a combination of specific symptoms (nasal obstruction and/or rhinorrhoea, combined with loss of smell and/or facial pressure/fullness) and abnormalities upon nasal endoscopy and/or imaging<sup>(3)</sup>. CRS has a marked influence on health-related quality of life, and results in major health care costs<sup>(4,5)</sup>.

Currently, there is no cure for CRS and, as such, treatment should be aimed at attaining (some level of) disease control. Especially in this respect, the patient perspective on CRS is pivotal in determining treatment success. Over the past decades, several patient-reported outcome measures (PROMs) have been developed in the field of CRS. The 22-item SinoNasal Outcome Test (SNOT-22) is a widely accepted tool to measure disease-specific health-related quality of life (HRQoL)<sup>(6)</sup>. It is suggested as part

of the Core Outcome Set for CRS research<sup>(7)</sup>, and is used in large clinical trials as primary outcome measure<sup>(8-10)</sup>.

The SNOT-22 was originally developed in 2009 as a modification of a 20-item questionnaire (SNOT-20), which in turn was derived from the 31-item Rhinosinusitis Outcome Measure (RSOM-31)<sup>(6)</sup>. Since then, the SNOT-22 has been translated and validated in many languages<sup>(11-28)</sup>. In-depth analyses of SNOT-22 metrics, such as the minimal clinically important difference have been performed as well<sup>(29)</sup>.

The items in the SNOT-22 are not limited to nasal complaints only; the different domains also cover emotional complaints, and other physical areas, such as otologic symptoms. It is therefore not surprising that conditions or treatments affecting these domains, can influence SNOT-22 scores<sup>(30-32)</sup>.

With the recent advent of biological therapy for CRS with nasal

polyps, a new emphasis is placed on PROMs such as the SNOT-22. It is used as one of the indication criteria to start biological therapy, and as a measure of treatment success as well<sup>(3)</sup>. Given the high costs of biological therapy, the debate of benefit over costs will require patient-reported input, and it is very likely the SNOT-22 will play an essential role in this discussion. Post-hoc analyses and real-life studies<sup>(33-38)</sup> already confirm the effectiveness of the three currently registered biologicals for CRS with nasal polyps (mepolizumab<sup>(39)</sup>, dupilumab<sup>(40)</sup>, and omalizumab<sup>(41)</sup>). Still, the patient perspective in these analyses and their effect on treatment algorithms is essential<sup>(42)</sup>.

Although commonly used in many clinics in the Netherlands, the Dutch version of the SNOT-22 has not been validated yet. The aim of this study was to translate and validate the SNOT-22 for Dutch-speaking patients. We assessed the reliability, validity and responsiveness of the translated SNOT-22 questionnaire.

## Materials and methods

### SNOT-22

The SNOT-22 consists of 22 questions, 12 of which are relating to symptoms, (rhinologic, ear and facial symptoms), and 10 of which concern general health questions (sleep function and psychological issues). Per item, symptom severity is graded from 0 to 5: no problem (0), very mild problem (1), mild or slight problem (2), moderate problem (3), severe problem (4) and problem as bad as it can be (5). The total sum of item-scores can thus range from zero to 110 with higher scores indicating more severe disease.

### Forward and backward translation

A professional translator translated the questionnaire from English into Dutch. The study group then evaluated that the meaning of the wording preserved that of the original English version. Next, the backward translation was again performed by a professional translator. Any deviations from the original English SNOT-22 were studied, and none were deemed relevant. The final Dutch SNOT-22 is provided as online supplemental material.

### Study population

This study was approved by the Ethics Committee of the Amsterdam University Medical Centres, location AMC (W21\_195 # 21.212). Three groups were defined. Group A consisted of adult patients (18 years or older) with CRS (based on EPOS criteria) visiting the outpatient clinic of the AMC. They were asked to fill in the Dutch SNOT-22 as part of their regular care, irrespective of their current disease control (baseline measurement). If patients agreed to participate, they were given a blank SNOT-22, and a small questionnaire for identification and to indicate whether their health status had changed over the past weeks. Patients

Table 1. Baseline characteristics of the study groups.

Group	A: test – retest	B: dupilumab treatment	C: healthy controls
N	22	23	75
Age (mean ± SD)	56.1 ± 11.0	50.7 ± 10.2	46.2 ± 13.2
Gender (n (%) female)	9 (40.9%)	7 (30.4%)	36 (48.0%)
Smoking (n (%))			
- Never	14 (63.6%)	12 (52.2%)	65 (86.7%)
- Former	7 (31.8%)	11 (47.8%)	5 (6.7%)
- Current	1 (4.5%)	0 (0%) <sup>^</sup>	5 (6.7%)

<sup>^</sup> Smoking is a contra-indication for biological treatment in the Netherlands.

were given a return envelope, and asked to return these questionnaires after 2-4 weeks (follow-up measurement). Only patients returning a complete SNOT-22 within 4 weeks, and indicating no change in health status were included in the analysis (n=22). Group B consisted of 23 adult CRS patients starting on biological therapy (dupilumab). This group was formed to assess the responsiveness of the Dutch SNOT-22. Patients filled in a Dutch SNOT-22 as part of their regular care at the start of treatment (baseline measurement) and after 4 weeks (follow-up measurement; i.e. after two gifts of 300 mg dupilumab s.c.). Group C consisted of adult healthy native Dutch volunteers that were recruited from the close circle of the study team members: a local padel club, a local tennis club, non-direct neighbours and family members from medical staff. Participation was voluntary. Information on the aim of the study was provided. The volunteers were asked to fill in the Dutch SNOT-22, along with a small questionnaire regarding baseline characteristics (age, gender, smoking), and whether they had ever been diagnosed with, or treated for (non-)allergic rhinitis, CRS, or asthma. Those confirming such a medical history were excluded from this group. This way, 75 subjects could be included in group C.

### Statistical analysis

Data were analysed in SPSS (IBM SPSS Statistics, version 26). Data are presented as mean ± standard deviation, unless otherwise specified. In group A, a Pearson correlation test was used. In group B, a paired-samples t-test was used; differences between group B and C were tested with an uncorrected independent-samples t-test. Internal consistency was tested using Cronbach's alpha, both for the full SNOT-22, as by item-wise determination when leaving out a single question. A p-value <0.05 was considered significant.

## Results

The baseline characteristics for the three groups are given in Ta-




Figure 1. Left panel: outcomes for group A (test-retest): the x-axis shows the SNOT-22 scores at the baseline test; the y-axis shows those after 2-4 weeks. Dots indicate single patient outcomes. There is an excellent correlation between the two (dotted line). Right panel: SNOT-22 scores for group B before (orange dots) and after (blue dots) 4 weeks of dupilumab, and for group C (healthy controls; grey dots). Horizontal bars indicate the group mean SNOT-22 score. \*\*\*  $p < 0.0001$ .

ble 1. For group A, the left panel of Figure 1 shows the baseline and retest measurements, with a Pearson correlation coefficient of 0.968, indicating excellent correlation ( $p < 0.0001$ ).

The right panel of Figure 1 shows the data from the dupilumab treated patients, starting at a mean SNOT-22 score of  $57.4 \pm 16.6$ . After four weeks of dupilumab treatment, this decreased to  $29.6 \pm 16.7$  ( $p < 0.0001$ ). The data from group C are also summarized in this panel. The mean SNOT-22 score for healthy controls was  $11.8 \pm 8.5$  ( $p < 0.0001$  versus group B baseline and after 4 weeks of dupilumab). In this group, no effect on the SNOT-22 score was found for age, gender, or smoking (not shown).

Cronbach's alpha was 0.958 in group A for the baseline measurement, and 0.960 for the retest; in group B it was 0.901 at baseline, and 0.928 after 4 weeks of treatment with dupilumab. Item-wise analysis of Cronbach's alpha when deleting a single question showed a value of  $\geq 0.893$  in these groups.

## Discussion

The current study shows that the Dutch version of the SNOT-22 is robust, valid, responsive, and has a good to excellent internal consistency. This is in line with the other studies describing its translation and validation in other languages. It validates the already common use of the SNOT-22 in Dutch clinics.

The limitations of the study include a relatively small sample size in groups A and B. Given the fact that group A covers a large range of SNOT-22 scores, we would not expect a large sample to give significantly different results. For group B the effects

are already quite drastic and in line with a larger cohort using dupilumab<sup>(38)</sup>; therefore, we would not expect relevant changes from expanding this group either.

Another limitation is the recruitment of patients from a tertiary clinic, possibly leading to selection bias of more severe patients. The distribution of the SNOT-22 scores in group A suggests that this bias is limited.

Finally, strictly speaking it would be necessary to revalidate the Dutch SNOT-22 in other Dutch speaking areas such as parts of Belgium, or the former Dutch colonies, although it is very likely the current Dutch version can be used reliably in these patient / demographic groups as well.

## Conclusions

The presented Dutch version of the SNOT-22 is valid and reliable and can be used to measure HRQoL in Dutch CRS patients.

## Acknowledgments

Not applicable.

## Funding

There was no specific funding for this work.

## Authorship contribution

DDdL, WJF and SR designed the study and recruited the subjects. DDdL and SR constructed the database, analysed the data, and wrote the manuscript. All authors interpreted the data and reviewed the manuscript.

### Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Amsterdam University Medical Centres, location AMC (W21\_195 # 21.212).

### Consent for publication

Not applicable.

### Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### Conflict of interest

None declared. WJF and SR are associated with the journal as (associate) editor, but were not involved in the reviewing process nor the decision to accept the paper.

### References

1. Dietz de Loos D, Lourijzen ES, Wildeman MAM, et al. Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. *J Allergy Clin Immunol*. 2019;143(3):1207-14.
2. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe—an underestimated disease. A GA(2)LEN study. *Allergy*. 2011;66(9):1216-23.
3. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology*. 2020;58(Suppl S29):1-464.
4. Lourijzen ES, Fokkens WJ, Reitsma S. Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps. *Rhinology*. 2020;58(3):213-7.
5. Wahid NW, Smith R, Clark A, Salam M, Philpott CM. The socioeconomic cost of chronic rhinosinusitis study. *Rhinology*. 2020;58(2):112-25.
6. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. *Clin Otolaryngol*. 2009;34(5):447-54.
7. Hopkins C, Hettige R, Soni-Jaiswal A, et al. Chronic Rhinosinusitis Outcome Measures (CHROME), developing a core outcome set for trials of interventions in chronic rhinosinusitis. *Rhinology*. 2018;56(1):22-32.
8. Lourijzen ES, Reitsma S, Vleming M, et al. Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial. *Lancet Respir Med*. 2022;10(4):337-46.
9. Lourijzen ES, Vleming M, Reitsma S, Fokkens WJ. Endoscopic sinus surgery in adult patients with Chronic Rhinosinusitis with nasal polyps (PolypESS) - statistical analysis plan for a multicentre randomised controlled trial. *Rhinology online*. 2021;4(1):58-65.
10. Lilja MJ, Virkkula P, Hammaren-Malmi S, et al. The extent of endoscopic sinus surgery in patients with severe chronic rhinosinusitis with nasal polyps (AirGOs Operative). *Rhinology online*. 2021;4(1):154-60.
11. Adnane C, Adouly T, Oubahmane T, et al. Psychometric Validation of a Moroccan Version of the 22-Item Sino-Nasal Outcome Test. *Otolaryngol Head Neck Surg*. 2016;155(4):681-7.
12. Alanazy F, Dousary SA, Albosaily A, Aldriweesh T, Alsaleh S, Aldrees T. Psychometric Arabic Sino-Nasal Outcome Test-22: validation and translation in chronic rhinosinusitis patients. *Ann Saudi Med*. 2018;38(1):22-7.
13. de Dorlodot C, Horoi M, Lefebvre P, et al. French adaptation and validation of the sino-nasal outcome test-22: a prospective cohort study on quality of life among 422 subjects. *Clin Otolaryngol*. 2015;40(1):29-35.
14. de Vilhena D, Duarte D, Lopes G, Sino-Nasal Outcome Test-22: translation, cultural adaptation and validation in Portugal. *Clin Otolaryngol*. 2016;41(1):21-4.
15. Eisenbach N, Matot S, Nemet A, Sela E, Marshak T, Ronen O. Sino-nasal outcome test-22: Cross-cultural adaptation and validation in Russian speaking patients. *Clin Otolaryngol*. 2020;45(3):350-6.
16. Jalessi M, Farhadi M, Kamrava SK, et al. The reliability and validity of the persian version of sinonasal outcome test 22 (snot 22) questionnaires. *Iran Red Crescent Med J*. 2013;15(5):404-8.
17. Koskinen A, Hammaren-Malmi S, Myller J, et al. Translation, cross-cultural adaptation, and validation of the sino-nasal outcome test (snot)-22 for Finnish patients. *Eur Arch Otorhinolaryngol*. 2021;278(2):405-10.
18. Kosugi EM, Chen VG, Fonseca VM, Cursino MM, Mendes Neto JA, Gregorio LC. Translation, cross-cultural adaptation and validation of SinoNasal Outcome Test (SNOT): 22 to Brazilian Portuguese. *Braz J Otorhinolaryngol*. 2011;77(5):663-9.
19. Lachanas VA, Tsea M, Tsiouvaka S, Hajjiioannou JK, Skoulakis CE, Bizakis JG. The sino-nasal outcome test (SNOT)-22: validation for Greek patients. *Eur Arch Otorhinolaryngol*. 2014;271(10):2723-8.
20. Lange B, Thilsing T, Al-kalemji A, Baelum J, Martinussen T, Kjeldsen A. The Sino-Nasal Outcome Test 22 validated for Danish patients. *Dan Med Bull*. 2011;58(2):A4235.
21. Mozzanica F, Preti A, Gera R, et al. Cross-cultural adaptation and validation of the SNOT-22 into Italian. *Eur Arch Otorhinolaryngol*. 2017;274(2):887-95.
22. Numthavaj P, Bhongmakapat T, Roongpuwabaht B, Ingsathit A, Thakkestian A. The validity and reliability of Thai Sinonasal Outcome Test-22. *Eur Arch Otorhinolaryngol*. 2017;274(1):289-95.
23. Plaas M, Kasenomm, P. The Sino-Nasal Outcome Test-22: translation and validation in an Estonian population. *Rhinology online*. 2019;2(1):87-90.
24. Riedl D, Dejacco D, Steinbichler TB, et al. Assessment of health-related quality-of-life in patients with chronic Rhinosinusitis - Validation of the German Sino-Nasal Outcome Test-22 (German-SNOT-22). *J Psychosom Res*. 2021;140:110316.
25. Schalek P, Otruba L, Hahn A. Quality of life in patients with chronic rhinosinusitis: a validation of the Czech version of SNOT-22 questionnaire. *Eur Arch Otorhinolaryngol*. 2010;267(3):473-5.
26. Shapira Galitz Y, Halperin D, Bavnik Y, Warman M. Sino-Nasal Outcome Test-22: Translation, Cross-cultural Adaptation, and Validation in Hebrew-Speaking Patients. *Otolaryngol Head Neck Surg*. 2016;154(5):951-6.
27. Vaitkus S, Padervinskis E, Balsevicius T, et al. Translation, cross-cultural adaptation, and validation of the sino-nasal outcome test (SNOT)-22 for Lithuanian patients. *Eur Arch Otorhinolaryngol*. 2013;270(6):1843-8.
28. Phillips KM, Houssein FA, Boeckermann LM, Singerman KW, Liu DT, Sedaghat AR. Multi-institutional minimal clinically important difference of the 22-item Sinonasal Outcome Test in medically managed chronic rhinosinusitis. *Rhinology*. 2021;59(6):552-9.
29. Phillips KM, Sedaghat AR. Depression and Anxiety: Considerations for Interpretation of the SNOT-22 (22-Item Sinonasal Outcome Test). *Otolaryngol Head Neck Surg*. 2022;166(5):985-92.
30. Bengtsson C, Jonsson L, Theorell-Haglow J, Holmstrom M, Janson C, Lindberg E. Sinonasal outcome test-22 and peak nasal inspiratory flow - valuable tools in obstructive sleep apnoea. *Rhinology*. 2020;58(4):341-8.
31. Thorsberger M, Porsbjerg C, Yde J, Aanaes K. Effects on hearing and tinnitus following Dupilumab treatment of severe asthma with chronic rhinosinusitis - a case report. *Rhinology online*. 2021;4(1):73-6.
32. Bachert C, Zinreich SJ, Hellings PW, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients

- with CRSwNP. *Rhinology*. 2020;58(1):10-7.
34. Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. *Rhinology*. 2021;59(3):301-11.
  35. Forster-Ruhrmann U, Stergioudi D, Pierchalla G, Fluhr JW, Bergmann KC, Olze H. Omalizumab in patients with NSAIDs-exacerbated respiratory disease. *Rhinology*. 2020;58(3):226-32.
  36. Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP. *Rhinology*. 2021;59(2):151-63.
  37. Laidlaw TM, Bachert C, Amin N, et al. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. *Ann Allergy Asthma Immunol*. 2021;126(5):584-92 e1.
  38. Lans R, Fokkens WJ, Adriaansen G, Hoven DR, Drubbel JJ, Reitsma S. Real-life observational cohort verifies high efficacy of dupilumab for Chronic Rhinosinusitis with Nasal Polyps. *Allergy*. 2022 Feb;77(2):670-674.
  39. Han JK, Bachert C, Fokkens WJ, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2021;9(10):1141-53.
  40. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019;394(10209):1638-50.
  41. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. *J Allergy Clin Immunol*. 2020;146(3):595-605.
  42. Hopkins C, Surda P, Walker A, Wolf A, Speth M, Jacques T, et al. EPOS 4 patients. *Rhinology*. 59, 2021 Suppl. 30: 1-57. doi: 10.4193/Rhin20.950.

**Sietze Reitsma, MD, PhD**

**Afdeling KNO**

**Meibergdreef 9**

**1105 AZ Amsterdam**

**The Netherlands**

**T: +31-20-5663789**

**E: s.reitsma@amsterdamumc.nl**

## SNOT-22

### Uitkomstmeting (neus)bijholteontsteking

Hieronder vindt u een lijst met de symptomen, functionele beperkingen en emotionele gevolgen van uw (neus)bijholteklachten. We willen graag meer weten over deze klachten en zouden het op prijs stellen als u de volgende vragen zo goed mogelijk zou willen beantwoorden. Er zijn geen 'goede' of 'foute' antwoorden en alleen u kunt ons aan deze informatie helpen. Beoordeel uw problemen zoals deze de afgelopen twee weken zijn geweest. Aarzel niet om de onderzoeksassistent of een van de medewerkers om hulp te vragen. Bedankt voor uw medewerking!

#### Mate van Ernst

Bekijk hoe ernstig het probleem is, als het zich manifesteert en hoe vaak het zich voordoet. Geef voor elke vraag aan hoe 'slecht' het gesteld is. Gebruik daarbij de onderstaande schaalverdeling:

- 0 = Niet aanwezig / geen probleem
- 1 = Minimaal probleem
- 2 = Matig / klein probleem
- 3 = Gemiddeld probleem
- 4 = Ernstig probleem
- 5 = Probleem 'is zo erg als het maar zijn kan'

#### Neusklachten

	Ernst					
1. Verstopte neus.....	0	1	2	3	4	5
2. Loopneus.....	0	1	2	3	4	5
3. Niezen.....	0	1	2	3	4	5
4. Verminderde reuk of smaak.....	0	1	2	3	4	5
5. Slijm dat van achteruit de neus in de keel loopt (postnasale drip) .....	0	1	2	3	4	5
6. Taai snot.....	0	1	2	3	4	5

#### Slaapproblemen

	Ernst					
7. Moeite om in slaap te komen.....	0	1	2	3	4	5
8. Midden in de nacht wakker worden.....	0	1	2	3	4	5
9. Gebrek aan een goede nachtrust.....	0	1	2	3	4	5
10. Vermoeid wakker worden.....	0	1	2	3	4	5

#### Oorklachten

	Ernst					
11. Dichte oren.....	0	1	2	3	4	5
12. Duizeligheid.....	0	1	2	3	4	5
13. Oorpijn.....	0	1	2	3	4	5

#### Algemene klachten

	Ernst					
14. Moeheid / uitgeput gevoel.....	0	1	2	3	4	5
15. Verminderde productiviteit.....	0	1	2	3	4	5
16. Slechte concentratie.....	0	1	2	3	4	5
17. Aangezichtspijn of drukkend gevoel.....	0	1	2	3	4	5
18. Hoesten.....	0	1	2	3	4	5

#### Praktische problemen

	Ernst					
19. Behoeft om herhaaldelijk de neus te snuiten.....	0	1	2	3	4	5

#### Emotionele gevolgen

	Ernst					
20. Gefrustreerd, ongeduldig of geïrriteerd..	0	1	2	3	4	5
21. Sombor gevoel.....	0	1	2	3	4	5
22. Opgelaten door uw symptomen.....	0	1	2	3	4	5

Bedankt voor uw medewerking!